Eisai Co Ltd and Biogen Inc will move forward with late-stage clinical trials of their new Alzheimer’s drug, BAN2401. The companies are working with regulators to design the next studies and gain expedited review as a breakthrough therapy. The companies announced this month that despite poor results at an earlier stage, BAN2401 slowed Alzheimer’s progression at its highest possible dose, providing renewed hope for effective treatment of the debilitating disease. In interviews with Reuters, Japanese drugmaker Eisai said the treatment also generated positive trial results at lower doses.